Logo Logo
Group by: Item Type | Date
Jump to: 2019 | 2012 | 2009
Number of items: 3.

2019

Modest, Dominik P.; Martens, Uwe M.; Riera-Knorrenschild, Jörge; Greeve, Jobst; Florschuetz, Axel; Wessendorf, Swen; Ettrich, Thomas; Kanzler, Stephan; Noerenberg, Dominik; Ricke, Jens; Seidensticker, Max; Held, Swantje; Buechner-Steudel, Petra; Atzpodien, Jens; Heinemann, Volker; Seufferlein, Thomas; Tannapfel, Andrea; Reinacher-Schick, Anke C. and Geissler, Michael (2019): FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). In: Journal of Clinical Oncology, Vol. 37, No. 35

2012

Schimanski, Carl Christoph; Möhler, Markus; Schön, Michael; Cutsem, Eric van; Greil, Richard; Bechstein, Wolf Otto; Hegewisch-Becker, Susanna; Wichert, Götz von; Vöhringer, Matthias; Heike, Michael; Heinemann, Volker; Peeters, Marc; Kanzler, Stephan; Kasper, Stefan; Overkamp, Friedrich; Schröder, Jan; Seehofer, Daniel; Kullmann, Frank; Linz, Bernhard; Schmidtmann, Irene; Smith-Machnow, Victoria; Gockel, Ines; Lang, Hauke and Galle, Peter R. (2012): LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases-a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. In: BMC Cancer 12:144 [PDF, 1MB]

2009

Mihaljevic, Andre; Buechler, Peter; Harder, Jan; Hofheinz, Ralf; Gregor, Michael; Kanzler, Stephan; Schmiegel, Wolff; Heinemann, Volker; Endlicher, Esther; Kloeppel, Guenter; Seufferlein, Thomas and Geissler, Michael (2009): A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer. In: BMC Surgery 9:1 [PDF, 284kB]

This list was generated on Sun Apr 14 05:07:51 2024 CEST.